2023 ESC guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the …
2023 ESC Guidelines for the management of acute coronary syndromes Page 1 2023 ESC
Guidelines for the management of acute coronary syndromes Developed by the task force on …
Guidelines for the management of acute coronary syndromes Developed by the task force on …
Risk of major adverse cardiovascular events of CYP2C19 loss-of-function genotype guided prasugrel/ticagrelor vs clopidogrel therapy for acute coronary syndrome …
The most effective antiplatelet treatments for acute coronary syndrome (ACS) patients
carrying CYP2C19 loss-of-function (LoF) alleles undergoing percutaneous coronary …
carrying CYP2C19 loss-of-function (LoF) alleles undergoing percutaneous coronary …
Ticagrelor versus clopidogrel in patients with STEMI treated with fibrinolysis: TREAT trial
O Berwanger, RD Lopes, DDF Moia… - Journal of the American …, 2019 - jacc.org
Background: The efficacy of ticagrelor in the long-term post–ST-segment elevation
myocardial infarction (STEMI) treated with fibrinolytic therapy remains uncertain. Objectives …
myocardial infarction (STEMI) treated with fibrinolytic therapy remains uncertain. Objectives …
Ideal P2Y12 inhibitor in acute coronary syndrome: a review and current status
A Pradhan, A Tiwari, G Caminiti, C Salimei… - International Journal of …, 2022 - mdpi.com
Dual antiplatelet therapy (DAPT) has remained the cornerstone for management of acute
coronary syndrome (ACS) over the years. Clopidogrel has been the quintessential P2Y12 …
coronary syndrome (ACS) over the years. Clopidogrel has been the quintessential P2Y12 …
Systematic review with meta‐analysis: the risk of gastrointestinal bleeding in patients taking third‐generation P2Y12 inhibitors compared with clopidogrel
Background Ticagrelor and prasugrel are third‐generation oral P2Y12 receptor antagonists
with rapid onset and pronounced platelet inhibition. However, higher overall bleeding rates …
with rapid onset and pronounced platelet inhibition. However, higher overall bleeding rates …
The risk of dyspnea in patients treated with third-generation P2Y12 inhibitors compared with clopidogrel: a meta-analysis of randomized controlled trials
N Zhang, W Xu, O Li, B Zhang - BMC cardiovascular disorders, 2020 - Springer
Background Ticagrelor and prasugrel are two third-generation oral P2Y 12 inhibitors which
are more commonly used in clinical practice. However, dyspnea has been consecutively …
are more commonly used in clinical practice. However, dyspnea has been consecutively …
Efficacy and safety of low dose ticagrelor in patients with acute coronary syndrome: a systematic review and meta-analysis
Q Chen, Y Zhang, Z Wang, S Wang… - Postgraduate …, 2020 - academic.oup.com
Our aim was to examine clinical trials, provide guidance to practitioners and estimate the
efficacy and safety of two agents by comparing low dose ticagrelor with standard dose …
efficacy and safety of two agents by comparing low dose ticagrelor with standard dose …
Safety of Clopidogrel vs. Ticagrelor in Dual Antiplatelet Therapy Regimens for High-Bleeding Risk Acute Coronary Syndrome Patients: A Comprehensive Meta …
Introduction Patients of acute coronary syndrome (ACS) at a high-bleeding risk (HBR) often
require dual antiplatelet therapy (DAPT) to reduce the risk of recurrent cardiovascular …
require dual antiplatelet therapy (DAPT) to reduce the risk of recurrent cardiovascular …
Use of ticagrelor alongside fibrinolytic therapy in patients with ST‐segment elevation myocardial infarction: practical perspectives based on data from the TREAT study
O Berwanger, M Abdelhamid, T Alexander… - Clinical …, 2018 - Wiley Online Library
Primary percutaneous coronary intervention (PCI) is the preferred reperfusion method in
patients with ST‐segment elevation myocardial infarction (STEMI). In patients with STEMI …
patients with ST‐segment elevation myocardial infarction (STEMI). In patients with STEMI …
P2Y12 inhibitors for the treatment of acute coronary syndrome patients undergoing percutaneous coronary intervention: current understanding and outcomes
D Alexopoulos, C Varlamos, A Mpahara… - Expert Review of …, 2019 - Taylor & Francis
ABSTRACT Introduction: Inhibition of P2Y12 platelet receptors consists a crucial target of
pharmacologic treatment in acute coronary syndrome patients. Several controversial issues …
pharmacologic treatment in acute coronary syndrome patients. Several controversial issues …